GleamWall
中文EN

BMRN BIOMARIN PHARMACEUTICAL INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1048477 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.1%
TTM net income YoY-103.7%
TTM EPS YoY-103.7%
Revenue 3-yr CAGR16.5%
Net income 3-yr CAGR—

Margins

Gross margin76.0%
Operating margin3.1%
Net margin-0.5%
FCF margin15.3%
EBITDA margin4.7%

Returns

ROE-0.3%
ROA-0.2%
ROIC (approx.)0.8%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets45.9%
Debt / equity0.67x
Current ratio2.44x
Interest coverage0.89x

Cash quality & payout

Operating cash flow / net income-35.40x
Accruals ratio-7.3%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$3.22B$2.85B
Cost of revenue$717.44M$580.24M
Gross profit$2.50B$2.27B
R&D expense$921.93M$747.18M
SG&A expense$1.15B$1.01B
Operating income$409.48M$484.21M
Interest expense$10.90M$12.67M
Pretax income$482.48M$541.76M
Income tax$133.58M$114.90M
Net income$348.90M$426.86M
EBITDA$489.04M$580.64M
EPS (basic)1.822.25
EPS (diluted)1.802.21
Weighted avg. shares (diluted)197.39M196.71M
Balance sheet
Cash & equivalents$1.31B$942.84M
Short-term investments$248.93M$194.86M
Receivables$908.21M$660.53M
Inventory$1.30B$1.23B
Current assets$3.95B$3.23B
PP&E, net$952.51M$1.04B
Goodwill$196.20M$196.20M
Intangibles$213.84M$255.28M
Total assets$7.59B$6.99B
Current liabilities$759.03M$606.99M
Short-term debt$0—
Long-term debt$597.18M—
Total debt$597.18M—
Total liabilities$1.51B$1.33B
Shareholders' equity$6.09B$5.66B
Net debt-$714.50M—
Shares outstanding192.30M190.76M
Cash flow statement
Operating cash flow$827.99M$572.84M
Capital expenditure$103.04M$85.42M
Free cash flow$724.96M$487.42M
Investing cash flow-$414.24M$136.49M
Financing cash flow-$42.39M-$526.45M
Depreciation & amortization$79.56M$96.43M
Stock-based compensation$181.41M$201.57M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.